Pharmacokinetic (PK) Modelling
Warfarin is a racemic mixture of two enantiomers: S-warfarin and R-warfarin. Swarfarin is known to be 3-5 times more potent as a vitamin K antagonist than Rwarfarin and it is metabolised by CYP2C9. In this analysis, only S-warfarin was considered to describe the mechanism of action. A two-compartment model with firstorder input and first-order elimination was applied (see below). Since the free concentrations of the drug are responsible for the anticoagulant effect of the drug, protein binding of warfarin was taken into account for expressing unbound plasma levels. The concentration was imputed given established PK parameters because the study did not measure warfarin levels. 
